SG11201807540UA - Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis - Google Patents
Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosisInfo
- Publication number
- SG11201807540UA SG11201807540UA SG11201807540UA SG11201807540UA SG11201807540UA SG 11201807540U A SG11201807540U A SG 11201807540UA SG 11201807540U A SG11201807540U A SG 11201807540UA SG 11201807540U A SG11201807540U A SG 11201807540UA SG 11201807540U A SG11201807540U A SG 11201807540UA
- Authority
- SG
- Singapore
- Prior art keywords
- wittelaan
- mechelen
- galapagos
- generaal
- international
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603745.9A GB201603745D0 (en) | 2016-03-04 | 2016-03-04 | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
| PCT/EP2017/054139 WO2017148787A1 (fr) | 2016-03-04 | 2017-02-23 | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de la fibrose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807540UA true SG11201807540UA (en) | 2018-09-27 |
Family
ID=55858990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807540UA SG11201807540UA (en) | 2016-03-04 | 2017-02-23 | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20190388421A1 (fr) |
| EP (1) | EP3423445B1 (fr) |
| JP (1) | JP2019507766A (fr) |
| KR (1) | KR20180118752A (fr) |
| CN (1) | CN108699037A (fr) |
| AR (1) | AR107798A1 (fr) |
| AU (1) | AU2017227900A1 (fr) |
| BR (1) | BR112018067312A2 (fr) |
| CA (1) | CA3016185A1 (fr) |
| CO (1) | CO2018009876A2 (fr) |
| GB (1) | GB201603745D0 (fr) |
| IL (1) | IL261444A (fr) |
| MX (1) | MX2018010218A (fr) |
| PH (1) | PH12018501849A1 (fr) |
| RU (1) | RU2018134780A (fr) |
| SG (1) | SG11201807540UA (fr) |
| TW (1) | TW201734005A (fr) |
| WO (1) | WO2017148787A1 (fr) |
| ZA (1) | ZA201805601B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3706728A1 (fr) | 2017-11-08 | 2020-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonistes de s1pr2 destinés au traitement de maladies impliquant des réponses immunitaires anormales |
| RU2020119415A (ru) | 2017-11-15 | 2021-12-16 | Галапагос Нв | Соединения и их фармацевтические композиции для применения при лечении фиброзных заболеваний |
| CN110878086B (zh) * | 2018-09-06 | 2024-06-07 | 青岛清原化合物有限公司 | 五元环取代的哒嗪醇类化合物及其衍生物、制备方法、除草组合物和应用 |
| WO2019148851A1 (fr) * | 2018-02-02 | 2019-08-08 | 青岛清原化合物有限公司 | Composé de pyridazinol substitué par un cycle à cinq chaînons et ses dérivés, procédé de préparation, composition herbicide et application |
| CN109053693B (zh) * | 2018-09-20 | 2021-02-05 | 顺毅股份有限公司 | 哒嗪胺类化合物的制备及其应用 |
| CN110128457B (zh) * | 2019-05-24 | 2022-05-03 | 宁波瑞奇医药科技有限公司 | 杂环小分子化合物的制备方法 |
| US11485727B2 (en) * | 2019-07-22 | 2022-11-01 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators |
| US11465982B2 (en) * | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
| CN111777549A (zh) * | 2020-07-07 | 2020-10-16 | 中瀚(齐河县)生物医药科技有限公司 | 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺 |
| WO2023069721A2 (fr) * | 2021-10-22 | 2023-04-27 | Carmot Therapeutics, Inc. | Dérivés de l'oxazole, de l'oxadiazole et de l'indole pour l'inhibition d'usp28 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000047207A1 (fr) * | 1999-02-09 | 2000-08-17 | Bristol-Myers Squibb Company | Inhibiteurs lactame de fxa et methode |
| WO2009042485A1 (fr) * | 2007-09-24 | 2009-04-02 | Allergan, Inc. | Composés de type indole porteur de groupes hétéroaryles ayant une activité biologique de récepteur de la sphingosine-1-phosphate (s1p) |
-
2016
- 2016-03-04 GB GBGB1603745.9A patent/GB201603745D0/en not_active Ceased
-
2017
- 2017-02-23 BR BR112018067312A patent/BR112018067312A2/pt not_active Application Discontinuation
- 2017-02-23 KR KR1020187028440A patent/KR20180118752A/ko unknown
- 2017-02-23 JP JP2018546507A patent/JP2019507766A/ja active Pending
- 2017-02-23 EP EP17706783.2A patent/EP3423445B1/fr active Active
- 2017-02-23 AU AU2017227900A patent/AU2017227900A1/en not_active Abandoned
- 2017-02-23 RU RU2018134780A patent/RU2018134780A/ru not_active Application Discontinuation
- 2017-02-23 WO PCT/EP2017/054139 patent/WO2017148787A1/fr active Application Filing
- 2017-02-23 SG SG11201807540UA patent/SG11201807540UA/en unknown
- 2017-02-23 US US16/081,797 patent/US20190388421A1/en not_active Abandoned
- 2017-02-23 MX MX2018010218A patent/MX2018010218A/es unknown
- 2017-02-23 CA CA3016185A patent/CA3016185A1/fr not_active Abandoned
- 2017-02-23 CN CN201780015118.3A patent/CN108699037A/zh active Pending
- 2017-03-03 TW TW106107104A patent/TW201734005A/zh unknown
- 2017-03-03 AR ARP170100536A patent/AR107798A1/es unknown
-
2018
- 2018-08-22 ZA ZA2018/05601A patent/ZA201805601B/en unknown
- 2018-08-29 IL IL261444A patent/IL261444A/en unknown
- 2018-08-30 PH PH12018501849A patent/PH12018501849A1/en unknown
- 2018-09-19 CO CONC2018/0009876A patent/CO2018009876A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2018009876A2 (es) | 2018-10-10 |
| KR20180118752A (ko) | 2018-10-31 |
| PH12018501849A1 (en) | 2019-01-28 |
| JP2019507766A (ja) | 2019-03-22 |
| EP3423445A1 (fr) | 2019-01-09 |
| AR107798A1 (es) | 2018-06-06 |
| WO2017148787A1 (fr) | 2017-09-08 |
| GB201603745D0 (en) | 2016-04-20 |
| IL261444A (en) | 2018-10-31 |
| CA3016185A1 (fr) | 2017-09-08 |
| CN108699037A (zh) | 2018-10-23 |
| US20190388421A1 (en) | 2019-12-26 |
| MX2018010218A (es) | 2018-11-09 |
| AU2017227900A1 (en) | 2018-10-25 |
| TW201734005A (zh) | 2017-10-01 |
| ZA201805601B (en) | 2019-06-26 |
| RU2018134780A (ru) | 2020-04-06 |
| EP3423445B1 (fr) | 2020-04-01 |
| BR112018067312A2 (pt) | 2018-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| SG11201811590RA (en) | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors |